Research

From peer-reviewed publications to applied case studies, our work drives decisions and improves patient outcomes.

At RainCity Analytics, research is at the heart of what we do. We combine methodological depth with real-world application, producing evidence that stands out in the world’s leading journals and informs critical decisions by regulators, HTA bodies, and global health agencies.

With over 100 peer-reviewed publications and dozens of successful HTA submissions, our research has influenced treatment guidelines, supported access to innovative therapies, and advanced the science of HEOR.

Our Results

We have produced high-impact work with global pharmaceutical companies and multilateral agencies
Our team has a long-standing reputation for delivering results with both strategic and practical application, including publications in leading research journals
Our science has lead to regulatory and HTA submissions, driving approval, clinical guideline development and patient access to cutting-edge therapies
We have contributed to dozens of conference podium presentations, including multiple late-breaking orals at major clinical congresses
Our landmark studies have received media coverage underscoring the wide-ranging medical and commercial impact of our work
Our research has played a key role in global health initiatives, supporting meaningful change for millions of people living with HIV/AIDS, cancer, and immunological diseases
We have and continue to drive cutting-edge analytical advancements shaping clinical and HEOR science

Case Studies

Our case studies highlight how we translate complex evidence into actionable insights. Each project showcases the challenges faced, the methods applied, and the impact achieved.

Oncology

External control arm for CAR-T

Regulatory and HTA bodies now require robust comparative evidence, yet for novel therapies like CAR-T, randomized controlled trials are often not feasible. Because ZUMA-5 was a single-arm trial, an external control arm and statistical models that emulate clinical trials were needed.

Global Health

WHO HIV Guidelines

With nearly 40 million people living with HIV globally, mounting evidence pointed to the benefits of dolutegravir (TLD) over efavirenz (TLE). WHO needed to determine whether the evidence base supported switching regimens from a public health perspective.